Skip to main content

Table 1 Clinical variables

From: Identification of a transcriptome profile associated with improvement of organ function in septic shock patients after early supportive therapy

  Responders (n = 17) Non-responders (n = 14) P value
Demographic parameters
 Age, years 62.8 (18.4) 68.6 (20.7) 0.42
 Sex, female 5 (29%) 5 (36%) 0.71
 Body mass index, kg/m2 27.0 (4.6) 26.9 (6.4) 0.98
Source of infection
 Abdominal 5 (29%) 5 (36%) 0.22
 Respiratory 4 (24%) 7 (50%)
 Urinary tract 6 (35%) 1 (7%)
 Other 2 (12%) 1 (7%)
Clinical parameters
 Length of stay in ICU, days 6.2 (4.9) 11.9 (6.3) 0.01
 Length of stay in hospital, days 21.0 (18.6) 28.7 (17.9) 0.31
 Death in ICU 2 (12%) 4 (29%) 0.24
 Death in hospital 2 (12%) 5 (36%) 0.11
 APACHE II 23.1 (6.8) 25.1 (7.2) 0.42
 SOFA T1 11.6 (3.0) 12.4 (2.4) 0.39
 SOFA T2 6.1 (1.6) 11.4 (2.6) P <0.001
 Temperature, °C, T1 37.2 (1.2) 37.8 (1.2) 0.17
 Temperature, °C, T2 37.8 (0.8) 37.2 (0.8) 0.02
 Lactate, mmol/L, T1 4.0 (1.8) 5.3 (2.8) 0.17
 Lactate, mmol/L, T2 1.5 (0.8) 2.1 (0.9) 0.10
 SvcO2, %, T1 75.0 (5.57) 74.36 (7.72) 0.82
 SvcO2, %, T2 68.5 (6.84) 69.33 (9.38) 0.84
 Heart rate, bpm, T1 105.8 (28.8) 109.2 (17.7) 0.69
 Heart rate, bpm, T2 89.2 (23.2) 95.4 (21.8) 0.46
 Mean arterial pressure, mm Hg, T1 60.1 (4.7) 57.4 (7.3) 0.24
 Mean arterial pressure, mm Hg, T2 67.5 (9.9) 66.0 (7.0) 0.62
 Hydrocortisone T1 0 (0%) 0 (0%)
 Hydrocortisone T2 1 (6%) 0 (0%) 0.36
 Vasopressor treatment T1 17 (100%) 14 (100%) 0.36
 Vasopressor treatment T2 3 (18%) 14 (100%) P <0.001
 Norepinehrine dose, μg/kg per min, T1 0.26 (0.19) 0.49 (0.38) 0.06
 Norepinehrine dose, μg/kg per min, T2 0.09 (0.04) 0.24 (0.33) 0.12
 Fluid balance, mL, T1 2229 (2468) 3498 (1943) 0.12
 Fluid balance, mL, T2 135 (1203) 1566 (2062) 0.03
 Urinary output, mL, T1 1674 (745) 1194 (750) 0.09
 Urinary output, mL, T2 2273 (849) 2040 (1691) 0.65
 Creatinine, mg/dL, T1 1.73 (1.17) 1.65 (0.83) 0.83
 Creatinine, mg/dL, T2 1.20 (1.01) 1.46 (0.95) 0.46
 Renal replacement therapy T1 1 (6%) 0 (0%) 0.36
 Renal replacement therapy T2 0 (0%) 0 (0%)
 Mechanical ventilation T1 13 (76%) 13 (93%) 0.22
 Mechanical ventilation T2 9 (53%) 11 (79%) 0.14
 paO2/FiO2, mm Hg, T1 203.9 (110.5) 205.7 (147.4) 0.97
 paO2/FiO2, mm Hg, T2 271.0 (102.3) 219.4 (48.6) 0.08
 Total leukocyte count, 103/mm3, T1 15.92 (15.37) 15.35 (9.27) 0.90
 Total leukocyte count, 103/mm3, T2 14.08 (9.05) 16.76 (8.53) 0.42
 Lymphocyte count, 103/mm3, T1 0.85 (0.53) 1.00 (0.93) 0.60
 Lymphocyte count, 103/mm3, T2 0.90 (0.53) 0.72 (0.45) 0.34
 C-reactive protein, mg/L, T1 245.2 (127.1) 217.0 (156.0) 0.59
 C-reactive protein, mg/L, T2 224.2 (110.2) 248.1 (127.1) 0.59
 Fibrinogen, mg/L, T1 5.34 (2.30) 4.60 (1.10) 0.27
 Fibrinogen, mg/L, T2 5.98 (2.28) 5.81 (2.06) 0.85
  1. Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, ICU intensive care unit, paO2/FiO2 partial pressure of oxygen/fraction of inspired oxygen, SOFA Sequential Organ Function Assessment, SvcO2 central venous oxygen saturation
  2. Clinical characteristics of the patients divided in responders and non-responders at the two time points. Data are presented as mean (standard deviation) or frequency (percentage)